Intermede Investment Partners Ltd Makes New $60.35 Million Investment in DexCom, Inc. $DXCM

Intermede Investment Partners Ltd purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 909,307 shares of the medical device company’s stock, valued at approximately $60,351,000. DexCom makes up about 2.5% of Intermede Investment Partners Ltd’s holdings, making the stock its 20th biggest holding.

A number of other large investors also recently modified their holdings of the business. Trust Co. of Vermont lifted its holdings in shares of DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares during the last quarter. CVA Family Office LLC lifted its holdings in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares during the last quarter. Personal CFO Solutions LLC lifted its holdings in shares of DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after buying an additional 185 shares during the last quarter. Finally, Integrated Wealth Concepts LLC lifted its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $72.10 on Monday. The business has a fifty day simple moving average of $63.58 and a 200 day simple moving average of $66.02. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $27.82 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 1.19 and a beta of 1.40. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 2.57 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,112 shares of company stock valued at $379,990 over the last 90 days. 0.28% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Tuesday, March 24th. Citigroup reiterated a “buy” rating and set a $79.00 price target (down from $84.00) on shares of DexCom in a report on Monday, May 4th. Raymond James Financial set a $81.00 price target on DexCom in a report on Friday, May 1st. Finally, Barclays reiterated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.21.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.